echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > New crown vaccine sales PK: Coxing Zhongwei's half-year profit may exceed 45 billion yuan

    New crown vaccine sales PK: Coxing Zhongwei's half-year profit may exceed 45 billion yuan

    • Last Update: 2021-09-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, China Biopharmaceuticals released the 2021 semi-annual report.
    The financial report showed that the revenue for the first half of the year was 14.
    354 billion yuan, a year-on-year increase of 13.
    5%; the profit of the parent company was 8.
    48 billion yuan, a year-on-year increase of 583.
    6%
    .


    At the same time, the financial report stated that Kexing Zhongwei’s financial statements in the group were listed as associates and accounted for using the equity method.


    Based on China Biopharmaceutical’s 15.
    03% holding of Kexingzhong’s shares, the industry generally speculates that Kexingzhongwei’s net profit in the first half of the year should be around 45 billion yuan
    .

    Coxing Zhongwei's new crown inactivated vaccine "CoronaVac" is the second domestic new crown vaccine approved for marketing in China.
    It has been approved for emergency use or listed on conditions in more than 50 countries and will be released this year.
    It officially entered the WHO emergency use list in June
    .

    In April this year, the third phase of the original solution workshop of Kerrlife was completed and put into production in China, with an annual production capacity of more than 2 billion doses.
    In addition, it has vaccine production sites in Indonesia, Malaysia, Brazil, Turkey, and Egypt
    .


    According to the analysis of Guotai Junan Securities, based on the situation in the first half of this year, the annual production capacity of Kexing Zhongwei exceeded the designed production capacity by 2 billion doses


    At present, there are a total of 6 new coronavirus vaccines approved for marketing or emergency use in China, including 2 inactivated vaccines from Sinopharm Zhongsheng, 1 inactivated vaccine from Kexing Zhongwei, 1 adenovirus vector vaccine from Cansino Bio, and Zhifei Bio 1 recombinant protein vaccine and 1 inactivated vaccine from Kangtai Biological
    .

    The semi-annual report published by Cansino showed that the revenue for the first half of the year was 2.
    06 billion yuan, which was in line with the previously expected "to achieve operating income of 2 billion to 2.
    2 billion yuan"; the net profit achieved 937.
    1 million yuan, compared with a loss of 102 million yuan in the same period last year.
    Turning around for the first time
    .


    The financial report shows that this is mainly due to the company's emergency use authorization and domestic conditional listing approval from Mexico, Pakistan and other countries during the reporting period, which has a positive impact on revenue


    Zhifei Biological’s semi-annual report shows that in the first half of the year, its revenue was 13.
    171 billion yuan, and its parent net profit was 5.
    491 billion yuan, of which the wholly-owned subsidiary Zhifei Longkoma achieved 5.
    313 billion yuan in revenue and 3.
    449 billion yuan in net profit in the first half of the year
    .


    Research reports by many securities companies including Ping An Securities believe that taking into account the product structure of Longkoma and the fact that Mycobacterium vaccae for injection has not yet formed substantial sales in the first half of the year, it is estimated that Longkoma’s income mainly comes from the new crown vaccine


    In the first half of the year, Kangtai Biosciences revenue was 1.
    052 billion yuan, a year-on-year increase of 20.
    95%; net profit was 337 million yuan, a year-on-year increase of 29.
    54%, but the relevant data of the new crown vaccine was not specifically disclosed; and Sinopharm Group, which has two inactivated vaccines, China Biotechnology Because it is not a listed company, it has not released relevant detailed data
    .

    In addition, Fosun Pharma, which has been approved in Hong Kong and Macau, China, and BioNTech's mRNA new crown vaccine Fubitai recently disclosed relevant data
    .


    Fosun Pharma’s semi-annual report shows that during the reporting period, Fubitai achieved revenue of over 500 million yuan.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.